Jerini completes randomization in icatibant Ph III trial
German drugmaker Jerini AG says that the last patient has been randomized in a Phase III clinical trial of its investiagtional drug icatibant for the treatment of hereditary angioedema.
A total of 56 patients were treated at 26 clinical sites in the USA, Canada, Australia, and Latin America in a double-blind placebo-controlled study. Jens Schneider-Mergener, Jerini's chief executive, said the firm will complete the randomization of the European leg of the trial and continues to be on track to report top-line results for both studies in the third quarter of this year with the filing of a marketing authorization application for the agent for the treatment of HAE is planned for the end of the year with product launch expected in 2007.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze